{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:14:44Z","timestamp":1787901284955,"version":"build-2784847793"},"reference-count":21,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; Aims<\/jats:title>\n                    <jats:p>Accumulating data has shown the rising incidence and poor prognosis of early\u2010onset gastrointestinal cancers, but few data exist on biliary tract cancers (BTC). We aimed to analyse the clinico\u2010pathological, molecular, therapeutic characteristics and prognosis of patients with early onset BTC (EOBTC, age \u226450\u2009years at diagnosis), versus olders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed patients diagnosed with intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder adenocarcinoma between 1 January 2003 and 30 June 2021. Baseline characteristics and treatment were described in each group and compared. Progression\u2010free survival, overall survival and disease\u2010free survival were estimated in each group using the Kaplan\u2010Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 1256 patients were included, 188 (15%) with EOBTC. Patients with EOBTC demonstrated fewer comorbidities (63.5% vs. 84.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.0001), higher tumour stage (cT3\u20134: 50.0% vs. 32.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.0162), bilobar liver involvement (47.8% vs. 32.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.0002), and metastatic disease (67.6% vs. 57.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.0097) compared to older. Patients with EOBTC received second\u2010line therapy more frequently (89.5% vs. 81.0% non\u2010EOBTC,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.0224). For unresectable patients with BTC, median overall survival was 17.0 vs. 16.2\u2009months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.0876), and median progression\u2010free survival was 5.8 vs. 6.0\u2009months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.8293), in EOBTC vs. older. In advanced stages, fewer actionable alterations were found in EOBTC (e.g.,\n                      <jats:italic>IDH1<\/jats:italic>\n                      mutations [7.8% vs. 16.6%];\n                      <jats:italic>FGFR2<\/jats:italic>\n                      \u2010fusion [11.7% vs. 8.9%];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.029).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Patients with EOBTC have a more advanced disease at diagnosis, are treated more heavily at an advanced stage but show similar survival. A distinctive molecular profile enriched for\n                      <jats:italic>FGRF2<\/jats:italic>\n                      fusions was found.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/liv.15922","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T08:49:20Z","timestamp":1712566160000},"page":"1886-1899","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Management of biliary tract cancers in early\u2010onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort"],"prefix":"10.1111","volume":"44","author":[{"given":"Antoine","family":"Lebeaud","sequence":"first","affiliation":[{"name":"Department of Medical Oncology CHU Lille  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leony","family":"Antoun","sequence":"additional","affiliation":[{"name":"Gustave Roussy Cancer Campus  Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane\u2010Rose","family":"Paccard","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hepatogastroenterology Lyon University Hospital Center, Hospices Civiles de Lyon  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-7741","authenticated-orcid":false,"given":"Julien","family":"Edeline","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Centre Eug\u00e8ne Marquis  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8979-3972","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Bourien","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Centre Eug\u00e8ne Marquis  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim","family":"Fares","sequence":"additional","affiliation":[{"name":"Department of Digestive Oncology Centre Hospitalier Universitaire de Toulouse, H\u00f4pital Rangueil  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Tournigand","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Centre Hospitalier Universitaire Henri\u2010Mondor, AP\u2010HP  Creteil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lecomte","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology CHU de Tours, H\u00f4pital Trousseau  Chambray\u2010l\u00e8s\u2010Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tougeron","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology CHU Poitiers, H\u00f4pital Jean Bernard  Poitiers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Hautefeuille","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Digestive Oncology Department CHU Amiens\u2010Picardie \u2013 Site Nord  Amiens France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lique","family":"Vi\u00e9not","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology CHU Besancon, H\u00f4pital Jean Minjoz  Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Henriques","sequence":"additional","affiliation":[{"name":"University of Franche\u2010Comt\u00e9, EFS, INSERM, UMR RIGHT  Besan\u00e7on France"},{"name":"Methodology and Quality of Life Unit in Oncology, CHU Besan\u00e7on  Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Williet","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology University Hospital of Saint\u2010Etienne  Saint\u2010Etienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Baptiste","family":"Bachet","sequence":"additional","affiliation":[{"name":"Department of Hepato\u2010Gastroenterology and Digestive Oncology Groupe Hospitalier Piti\u00e9 Salpetriere  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Smolenschi","sequence":"additional","affiliation":[{"name":"Drug Development Department (DITEP) Gustave Roussy Cancer Campus  Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[{"name":"Drug Development Department (DITEP) Gustave Roussy Cancer Campus  Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal and Endocrine Tumor Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5416-5383","authenticated-orcid":false,"given":"Florian","family":"Castet","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal and Endocrine Tumor Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Malka","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Institut Mutualiste Montsouris  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Neuzillet","sequence":"additional","affiliation":[{"name":"Department of GI Oncology, Medical Oncology Curie Institute  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewi","family":"Vernerey","sequence":"additional","affiliation":[{"name":"University of Franche\u2010Comt\u00e9, EFS, INSERM, UMR RIGHT  Besan\u00e7on France"},{"name":"Methodology and Quality of Life Unit in Oncology, CHU Besan\u00e7on  Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Boil\u00e8ve","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Gustave Roussy  Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2282-0101","authenticated-orcid":false,"given":"Anthony","family":"Turpin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology CHU Lille  Lille France"},{"name":"CNRS INSERM UMR9020\u2010U1277, CANTHER Cancer Heterogeneity Plasticity and Resistance to Therapies Universit\u00e9 de Lille  Lille France"},{"name":"GERCOR  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00672-8"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2023-000049"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.010"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2200869"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.2380"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2022.04.003"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2019.04.036"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.5600"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2015.01.013"},{"key":"e_1_2_11_12_1","unstructured":"DefossezG.Estimations nationales de l'incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018 2019.https:\/\/www.santepubliquefrance.fr\/maladies\u2010et\u2010traumatismes\/cancers\/cancer\u2010du\u2010sein\/documents\/rapport\u2010synthese\/estimations\u2010nationales\u2010de\u2010l\u2010incidence\u2010et\u2010de\u2010la\u2010mortalite\u2010par\u2010cancer\u2010en\u2010france\u2010metropolitaine\u2010entre\u20101990\u2010et\u20102018\u2010volume\u20101\u2010tumeurs\u2010solides\u2010etud"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01439"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00594"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30915-X"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02008"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-018-0866-z"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113338"},{"issue":"1","key":"e_1_2_11_19_1","first-page":"42","article-title":"Early onset esophageal adenocarcinoma: a distinct molecular entity?","volume":"3","author":"Nistelrooij AMJ","year":"2016","journal-title":"Onco Targets Ther"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100324"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00027-9"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2384"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.15922","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.15922","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.15922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T19:05:46Z","timestamp":1772996746000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.15922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1111\/liv.15922"],"URL":"https:\/\/doi.org\/10.1111\/liv.15922","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"assertion":[{"value":"2024-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}